ECSP21034668A - Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento de cáncer - Google Patents

Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento de cáncer

Info

Publication number
ECSP21034668A
ECSP21034668A ECSENADI202134668A ECDI202134668A ECSP21034668A EC SP21034668 A ECSP21034668 A EC SP21034668A EC SENADI202134668 A ECSENADI202134668 A EC SENADI202134668A EC DI202134668 A ECDI202134668 A EC DI202134668A EC SP21034668 A ECSP21034668 A EC SP21034668A
Authority
EC
Ecuador
Prior art keywords
treatment
cancer
pirrolo
hpk1
ona
Prior art date
Application number
ECSENADI202134668A
Other languages
English (en)
Inventor
Mingying He
Dahui Zhou
Ru Zhou
Sajiv Krishnan Nair
Omar Khaled Ahmad
Anne-Marie Dechert Schmitt
Ted William Johnson
Bel Matthew L Del
Mehran Jalaie
Rebecca Anne Gallego
Robert Steven Kania
Jamison Bryce Tuttle
Michele Ann Mctigue
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68771726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP21034668(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP21034668A publication Critical patent/ECSP21034668A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos de la Fórmula general (I) y sales de estos aceptables desde el punto de vista farmacéutico, en donde R1, R1a, R2, , R3, R4, y (R5)a son como se definen en la presente, a composiciones farmacéuticas que comprenden dichos compuestos y sales de estos aceptables desde el punto de vista farmacéutico, y a métodos de uso de dichos compuestos, sales de estos aceptables desde el punto de vista farmacéutico y composiciones para el tratamiento del crecimiento anormal de células, que incluye cáncer.
ECSENADI202134668A 2018-11-15 2021-05-14 Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento de cáncer ECSP21034668A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862767602P 2018-11-15 2018-11-15
US201962909970P 2019-10-03 2019-10-03

Publications (1)

Publication Number Publication Date
ECSP21034668A true ECSP21034668A (es) 2021-06-30

Family

ID=68771726

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202134668A ECSP21034668A (es) 2018-11-15 2021-05-14 Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento de cáncer

Country Status (37)

Country Link
US (1) US11142525B2 (es)
EP (1) EP3880676B1 (es)
JP (1) JP7118267B2 (es)
KR (1) KR20210090675A (es)
CN (1) CN113316576A (es)
AU (1) AU2019378184B2 (es)
BR (1) BR112021008991A2 (es)
CA (1) CA3061392A1 (es)
CL (1) CL2021001190A1 (es)
CO (1) CO2021006114A2 (es)
CR (1) CR20210251A (es)
CU (1) CU20210035A7 (es)
DK (1) DK3880676T3 (es)
DO (1) DOP2021000088A (es)
EC (1) ECSP21034668A (es)
ES (1) ES2958948T3 (es)
FI (1) FI3880676T3 (es)
GE (2) GEAP202215630A (es)
HR (1) HRP20231089T1 (es)
HU (1) HUE063367T2 (es)
IL (1) IL283149A (es)
LT (1) LT3880676T (es)
MD (1) MD3880676T2 (es)
MX (1) MX2021005754A (es)
PE (1) PE20211868A1 (es)
PH (1) PH12021551117A1 (es)
PL (1) PL3880676T3 (es)
PT (1) PT3880676T (es)
PY (1) PY1996328A (es)
RS (1) RS64655B1 (es)
SG (1) SG11202104394XA (es)
SI (1) SI3880676T1 (es)
TW (1) TWI718758B (es)
UA (1) UA127426C2 (es)
UY (1) UY38471A (es)
WO (1) WO2020100027A1 (es)
ZA (1) ZA202103099B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3873903T3 (fi) 2018-10-31 2024-03-26 Gilead Sciences Inc Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
CN119874700A (zh) * 2019-09-13 2025-04-25 林伯士萨顿公司 Hpk1拮抗剂和其用途
IL297838A (en) * 2020-05-01 2023-01-01 Pfizer Azalactam compounds as hpk1 inhibitors
CN112409268A (zh) * 2020-12-03 2021-02-26 西南交通大学 靶向Fam20C抑制剂的制备及其抗三阴性乳腺癌作用
US11926625B2 (en) * 2021-03-05 2024-03-12 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
JP2024513011A (ja) 2021-03-29 2024-03-21 ニンバス サターン， インコーポレイテッド Ｈｐｋ１アンタゴニスト及びその使用
WO2022258044A1 (zh) * 2021-06-11 2022-12-15 杭州中美华东制药有限公司 吡咯并吡啶酮类化合物及其制备方法和用途
EP4373817B1 (en) 2021-07-20 2025-05-21 Astrazeneca AB Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer
WO2023023942A1 (en) * 2021-08-24 2023-03-02 Biofront Ltd (Cayman) Hpk1 inhibitors, compositions comprising hpk1 inhibitor, and methods of using the same
CN118103369A (zh) * 2021-09-03 2024-05-28 浙江海正药业股份有限公司 吡啶并内酰胺类衍生物及其制备方法和用途
US20240409559A1 (en) * 2021-10-05 2024-12-12 Pfizer Inc. Crystalline form of azalactam compound
CN114767676B (zh) 2022-04-22 2024-04-19 珠海宇繁生物科技有限责任公司 Hpk1激酶抑制剂在预防和/或治疗人的病原体感染中的应用
KR102855849B1 (ko) 2022-11-25 2025-09-08 충남대학교산학협력단 이미다조피리딘 유도체, 이를 유효성분으로 포함하는 약제학적 조성물 및 이를 이용하는 암의 치료 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5243049A (en) * 1992-01-22 1993-09-07 Neurogen Corporation Certain pyrroloquinolinones: a new class of GABA brain receptor ligands
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US8293747B2 (en) * 2007-07-19 2012-10-23 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
CN110225752B (zh) 2016-09-12 2023-05-05 整体健康 用作gpr120调节器的单环化合物
CN110402248B (zh) 2017-03-15 2023-01-06 豪夫迈·罗氏有限公司 作为hpk1抑制剂的氮杂吲哚类
TW201908306A (zh) 2017-07-18 2019-03-01 大陸商南京聖和藥業股份有限公司 作為ask抑制劑的雜環化合物及其應用
US20220324835A1 (en) 2018-01-26 2022-10-13 Nurix Therapeutics, Inc. Inhibitors of cbl-b and methods of use thereof

Also Published As

Publication number Publication date
PH12021551117A1 (en) 2021-11-22
WO2020100027A1 (en) 2020-05-22
IL283149A (en) 2021-06-30
CA3061392A1 (en) 2020-05-15
LT3880676T (lt) 2023-09-25
CR20210251A (es) 2021-07-14
HUE063367T2 (hu) 2024-01-28
MX2021005754A (es) 2021-08-11
SG11202104394XA (en) 2021-05-28
TWI718758B (zh) 2021-02-11
PT3880676T (pt) 2023-10-04
GEAP202215630A (en) 2022-06-27
TW202031657A (zh) 2020-09-01
BR112021008991A2 (pt) 2021-08-10
ZA202103099B (en) 2023-11-29
MD3880676T2 (ro) 2023-12-31
DK3880676T3 (da) 2023-09-04
JP7118267B2 (ja) 2022-08-15
PY1996328A (es) 2021-05-21
KR20210090675A (ko) 2021-07-20
HRP20231089T1 (hr) 2023-12-22
GEP20227434B (en) 2022-10-25
US20200172539A1 (en) 2020-06-04
UY38471A (es) 2020-06-30
PE20211868A1 (es) 2021-09-21
CN113316576A (zh) 2021-08-27
EP3880676A1 (en) 2021-09-22
EP3880676B1 (en) 2023-08-02
CO2021006114A2 (es) 2021-05-31
DOP2021000088A (es) 2021-06-30
RS64655B1 (sr) 2023-10-31
UA127426C2 (uk) 2023-08-16
AU2019378184A1 (en) 2021-05-27
FI3880676T3 (fi) 2023-09-15
JP2022507231A (ja) 2022-01-18
US11142525B2 (en) 2021-10-12
SI3880676T1 (sl) 2023-10-30
CL2021001190A1 (es) 2021-12-24
PL3880676T3 (pl) 2023-12-11
ES2958948T3 (es) 2024-02-16
CU20210035A7 (es) 2021-12-08
AU2019378184B2 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
ECSP21034668A (es) Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento de cáncer
UY38553A (es) Inhibidores de cdk2
NI201900013A (es) Inhibidor de piridopirimidinona cdk2/4/6
CR20200484A (es) COMPUESTOS DE DIHIDROISOQUINOLINONA SUSTITUIDA (Divisional 2016-0574)
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
MX2019003724A (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
UY39193A (es) Compuestos de azalactama como inhibidores de hpk1
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
GT201600091A (es) Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos
DOP2023000281A (es) Inhibidores de mutación de her2
SV2016005310A (es) Derivados de diheterociclo enlazado a cicloalquilo
MX2020013895A (es) Agentes inhibidores de ask1.
ECSP18056196A (es) Derivados de indano
MX2019014436A (es) Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa.
CU20140033A7 (es) Derivados de pirrolopirimidina y purina
ECSP17003149A (es) Compuestos de dihidroisoquinolinona sustituida
DOP2016000326A (es) Compuestos de dihidroisoquinolinona sustituida